Skip Navigation

Canine Oncology

Canine Study 1: Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog.


Title:

Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any dog weighing over 35 lbs that has been diagnosed with B cell Lymphoma and is being treated with prednisone alone.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy (other than prednisone) are not eligible for this study. Dogs with T cell lymphoma are not eligible for this study.

Owner Commitments:

Dogs will have an initial blood draw to isolate T cells from the blood. 6 weeks later, three infusion will begin. These will be given every other week for a total of 6 weeks. A blood sample collection will be necessary for the off weeks. 7-10 days after completion of therapy a biopsy of one lymph node and blood work will be collected. Animals will be sedated or anesthetized for the sample collection. Blood sample collections and physical exams will occur monthly thereafter.

Financial Incentives:

Immunophenotyping (determination of the type of lymphoma using special stains) will be done free of charge for all dogs with Lymphoma entering the study. The manufacturing of the T cell infusion and visit costs associated with these infusions will be paid for by the study.
This study is currently open.


Canine Study 2: Alteration of the intestinal microflora after chemotherapy in dogs.


Title:

Alteration of the intestinal microflora after chemotherapy in dogs.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Your dog must have a confirmed diagnosis of cancer and receive doxorubicin (a chemotherapy drug) as part of their treatment protocol. Two pretreatment fecal (stool) samples are needed and may be frozen before your first appointment.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs receiving probiotics of any type (e.g. Fortiflora ®) will be excluded. Dogs with significant pre-existing intestinal disease will also be excluded.

Owner Commitments:

You will be required to collect and bring in (or send in by mail) two pretreatment fecal samples as well as collect fecal sample the week before and 72 hours after doxorubicin chemotherapy. Blood will also be drawn at the first visit and possibly at subsequent visits for evaluation of B vitamin levels.

Financial Incentives:

All costs associated with this study will be provided as part of your participation. After entering the study fecal collection tubes will be provided and shipping for any samples will be paid. Costs associated with diagnosis, staging and doxorubicin therapy will be the responsibility of the owner.
This study is currently open. We have also partnered with Sugarland Veterinary Specialists.


Canine Study 3: S100b inhibitors for the treatment of canine malignant melanoma


Title:

S100b inhibitors for the treatment of canine malignant melanoma

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Your dog must have a confirmed diagnosis of melanoma and several tests to ensure his/her general health and to assess how advanced the disease is prior to treatment. The tumor will be biopsied prior to therapy. Tumors must be large enough to biopsy and your dog must have no other significant health problems.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs cannot be receiving concurrent chemotherapy (including corticosteroids) or radiation therapy. Dogs must be off of all such therapy for 3 weeks prior to study enrollment. No dogs under 15 kg (<33 lbs) will be allowed in this study.

Owner Commitments:

Prior to entry into this study, your dog must have a confirmed diagnosis of melanoma and staging tests to ensure his/her general health and to assess how advanced the disease is. The tumor will need to be biopsied before therapy for this purpose. Your dog will receive one of two drugs or a combination of the two. Both drugs are FDA approved and have been used in dogs previously for other reasons. Interactions between these drugs and other drugs are unknown; therefore it is important to tell your veterinarian about any medications (and supplements) your dog is currently taking. It is strongly encouraged to eliminate all unnecessary medications. This should be discussed with your oncologist if you have any questions.

Financial Incentives:

All costs associated with this study will be provided as part of your participation. In the event any complications arise during the twenty-nine (29) day study period (time period between drug administration and assessment), their management will be covered by study funds up to $750/dog. This would include any unanticipated hospitalizations. However, all costs exceeding $750/dog are your responsibilty.
This trial is currently open!


Canine Study 4: Radiation Therapy for dogs with multicentric lymphoma


Title:

Radiation Therapy for dogs with multicentric lymphoma

Contact Person:

Michael Deveau, MS, DVM, DAVR(Radiation Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any dog weighing over 10 lbs that has been newly diagnosed with lymphoma.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy (other than prednisone) are not eligible for this study.

Owner Commitments:

Dogs will receive full body imaging before therapy, then treated with chemotherapy for 19 weeks (stnadard therapy for canine lymphoma), after completion of chemotherapy dogs will receive 2 weeks (10 doses, M-F) of radiation therapy.

Financial Incentives:

The costs of the imaging associated with the study as well as some of the staging costs, radiation therapy costs, anesthesia costs and some blood work costs will be covered by this study. The cost of chemotherapy will be the responsibility of the owner.
This study is currently open!

 

Canine Study 5: Evaluation of new renal (kidney) biomarkers for kidney damage in normal dogs and dogs receiving nephrotoxic drugs.


Title:

Evaluation of new renal (kidney) biomarkers for kidney damage in normal dogs and dogs receiving nephrotoxic drugs.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs receiving kidney toxic drugs (e.g., tyrosine kinase inhibitors):

  • Must be at least 2 years old
  • Must weigh at least 22 lbs
  • Must have no previous history of kidney disease or protein in the urine
  • Must have a life expectancy of at least 4 months

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs with kidney disease, current urinary tract infections or protein in the urine are also excluded from this study.

Owner Commitments:

Dogs receiving Kidney toxic drugs (e.g., tyrosine kinase inhibitors) will participate for up to 6 months with a pretreatment blood and urine sample, and additional samples two weeks after initiation of therapy and then monthly thereafter.

Financial Incentives:

All laboratory tests associated with kidney panel will be covered by the study. Any additional costs or therapies will be the responsibility of the owner.
This trial is currently open!


Canine Study 6: Evaluation of a new therapy for dogs with any type of niave lymphoma.


Title:

Evaluation of a new therapy for dogs with any type of niave lymphoma.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs with any stage or type of lymphoma as long as they feel ok and have not received any prior treatments are eligible for this protocol.  Dogs must weigh at least 10 lbs and be able to travel to TAMU weekly for 13 consecutive weeks.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments:

Owners will be required to travel to TAMU weekly for 13 consecutive weeks. The first appointment is likely to take most of the business day; however, additional appointments will likely take 2-4 hours.

Financial Incentives:

All costs and fees associated with the trial are covered.  Additionally some of the staging costs will also be covered during the first visit if the dog is eligible. There is also a $750 fund to cover any side effects during the trial period. Any costs that exceed the side effects funds will be the responsibility of the owner.
This trial is currently open!

 

Canine Study 7: Evaluation of a new therapy, Leukothera, for the treatment of canine hematopoietic tumors (lymphoma, leukemia and multiple myeloma).


Title:

Evaluation of a new therapy, Leukothera, for the treatment of canine hematopoietic tumors (lymphoma, leukemia and multiple myeloma).

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs with a newly diagnosed or first relapse of any hematopoietic tumor (lymphoma, multiple myeloma or leukemia) with systemic disease (at least a stage III lymphoma) are eligible to enroll. Dogs must weigh at least 10 kg (22 lbs).

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments:

Dogs will be required to visit TAMU weekly for 5 weeks for treatment and therapy.  The initial visit costs are not covered by the study as we determine if your dog is eligible; however, once enrolled, all fees associated with the study will be covered.  Dogs will be required to come on the same day each week for approximately 3 hours each visit to be examined, run blood work and administer therapy.

Financial Incentives:

All costs associated with therapy after enrollment are covered by the study.  There is an additional $750 to help with any possible side effects your dog may experience.  Any costs beyond $750 for side effects will be the responsibility of the owner.

This trial is currently open and enrolling

 

Canine Study 8: Evaluation of a new therapy for dogs with Grade II or Grade III mast cell tumors (with visible tumors) that have not received any chemotherapy or radiation therapy with the exception of corticosteroids. Dogs who have previously had surgery but now have recurrence will qualify.


Title:

Evaluation of a new therapy for dogs with Grade II or Grade III mast cell tumors (with visible tumors) that have not received any chemotherapy or radiation therapy with the exception of corticosteroids. Dogs who have previously had surgery but now have recurrence will qualify.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs with qualifying mast cell tumors may enroll as long as they feel ok and have not received any prior treatments.  Dogs must weigh at least 10 lbs and be able to travel to TAMU weekly for 13 consecutive weeks.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments:

Owners will be required to travel to TAMU weekly for 13 consecutive weeks. The first appointment is likely to take most of the business day; however, additional appointments will likely take 2-4 hours.

Financial Incentives:

All costs and fees associated with the trial are covered.  Additionally some of the staging costs will also be covered during the first visit if the dog is eligible. There is also a $750 fund to cover any side effects during the trial period. Any costs that exceed the side effects funds will be the responsibility of the owner.
This trial is currently open!

 

Canine Trial 9: Evaluation of biomarkers as risk factors for lymphoma in Golden Retrievers.


Title:

Evaluation of biomarkers as risk factors for lymphoma in Golden Retrievers.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any golden retriever with lymphoma may qualify for this trial.

Exclusion Criteria:

Dogs without lymphoma or with other tumors may not qualify for this trial.

Owner Commitments:

Dogs will participate with a cheek swab on a one time bases.  Participation in this trial is expected to add no more than 30 minutes to the total visit time.

Financial Incentives:

There is no cost for participation in this trial. There are no financial benefits for participation in this trial.
This trial is currently open!

 

Canine Trial 10: Evaluation of DNA methylation patterns as risk factors for lymphoma in Golden Retrievers.


Title:

Evaluation of DNA methylation patterns as risk factors for lymphoma in Golden Retrievers.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any golden retriever with B cell lymphoma may qualify for this trial.

Exclusion Criteria:

Dogs without lymphoma or with other tumors may not qualify for this trial.

Owner Commitments:

Dogs will participate with a cheek swab on a one time bases.  Participation may include a biopsy of the lymph node, a fine needle aspirate of the lymph node and a blood sample. Participation may add 1-2 hours to the visit.

Financial Incentives:

There is no cost for participation in this trial. There are no financial benefits for participation in this trial.
This trial is currently open!